Format

Send to

Choose Destination
Hematol Oncol. 2018 Dec;36(5):740-748. doi: 10.1002/hon.2537. Epub 2018 Aug 3.

Precision immunotherapy, mutational landscape, and emerging tools to optimize clinical outcomes in patients with classical myeloproliferative neoplasms.

Author information

1
Tufts University Cancer Center, Boston, MA, USA.
2
Children's Cancer Research Institute, Medical University of Vienna, Vienna, Austria.
3
Memorial Sloan Kettering Cancer Center, New York, NY, USA.
4
UT Health San Antonio Cancer Center, San Antonio, TX, USA.
5
Oregan Health and Science University, Portland, OR, USA.
6
Greenebaum Cancer Center, University of Maryland, Baltimore, MD, USA.
7
MD Anderson Cancer Center, Houston, TX, USA.
8
Orbassano University Hospital, Turin, Italy.
9
University of California Irvine, Irvine, CA, USA.
10
Research Center for Molecular Medicine of the Austrian Academy of Science, Vienna, Austria.
11
Department of Laboratory Medicine, Medical University of Vienna, Vienna, Austria.

Abstract

Following the 47th American Society of Hematology Meeting in 2005, the late John Goldman and Tariq Mughal commenced a conference, the 1st Post-ASH Workshop, which brought together clinicians and scientists, to accelerate the adoption of new therapies for patients with myeloproliferative neoplasms (MPNs). The concept began with recognition of the CML success story following imatinib therapy, the discovery of JAK2V617F , and the demonstration that BCR-ABL1-negative MPNs are driven by abnormal JAK2 activation. This review is based on the presentations and deliberations at the XIIth Post-ASH Workshop on BCR-ABL1 positive and negative MPNs that took place on December 12 to 13, 2017, in Atlanta, Georgia, immediately following the 59th American Society of Hematology Meeting. We have selected some of the translational research and clinical topics, rather than an account of the proceedings. We discuss the role of immunotherapy in MPNs and the impact of the mutational landscape on TKI treatment in CML. We also consider how we might reduce TKI cardiovascular side effects, the potential role of nutrition as adjunctive nonpharmacologic intervention to reduce chronic inflammation in MPNs, and novel investigational therapies for MPNs.

KEYWORDS:

Chronic myeloroliferative neoplasms; genomics; immunotherapy; treatment

PMID:
30074634
PMCID:
PMC6613211
DOI:
10.1002/hon.2537
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Wiley Icon for PubMed Central
Loading ...
Support Center